ORCID as entered in ROS
![orcid_icon](/themes/resgate8/images/icons/ORCIDiD_icon24x24.png)
Select Publications
2009, 'HCV reinfection studies and the door to vaccine development', Journal of Hepatology, 51, pp. 628 - 631
,2009, 'Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents', Journal of Viral Hepatitis, 16, pp. 352 - 358
,2009, 'P214 Molecular epidemiology of newly acquired hepatitis C virus (HCV) infections in British Columbia', International Journal of Antimicrobial Agents, 34, pp. S95 - S95, http://dx.doi.org/10.1016/s0924-8579(09)70433-9
,2009, 'Primary drug resistance in chronically infected antiretroviral-naïve injection drug users.', International Journal of Infectious Diseases, 13, pp. 577 - 583
,2009, 'Reinfection with hepatitis C virus following sustained virological response in injection drug users', Journal of Gastroenterology and Hepatology, pp. no - no, http://dx.doi.org/10.1111/j.1440-1746.2009.06238.x
,2009, 'Systematic approach to the treatment of HCV infection in injection drug users: where are we now?', Future Virology, 4, pp. 411 - 413, http://www.futuremedicine.com/
,2009, 'Treatment of recent hepatitis C virus infection in a predominantly injection drug user cohort: the ATAHC Study', The Canadian Journal of Addiction, 1, pp. 33 - 33, http://dx.doi.org/10.1097/02024458-200912000-00072
,2008, 'Impact of HCV and HIV infections on mortality in a large community-based cohort of inner city residents', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 23, pp. A379 - A380, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000264953600118&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2008, 'Intermediate highly active antiretroviral therapy adherence thresholds and empirical models for the development of drug resistance mutations', Journal of Acquired Immune Deficiency Syndromes, 47, pp. 397 - 399, http://dx.doi.org/10.1097/QAI.0b013e31815b0d35
,2008, 'Current approaches to HCV infection in current and former injection drug users', Journal of Addictive Diseases, 27, pp. 25 - 35, http://dx.doi.org/10.1300/J069v27n02_04
,2008, 'Barriers associated with the treatment of hepatitis C virus infection among illicit drug users', Drug and Alcohol Dependence, 93, pp. 141 - 147, http://dx.doi.org/10.1016/j.drugalcdep.2007.09.008
,2008, 'Substitution of tenofovir for nucleoside analogues in virologically controlled HIV-infected patients co-infected with hepatitis C virus: TEN-SWITCH', Journal of the International AIDS Society, 11, pp. P277 - P277, http://dx.doi.org/10.1186/1758-2652-11-s1-p277
,2008, 'The role of re-infection in determining rates of spontaneous clearance after hepatitis C exposure', Journal of Hepatology, 49, pp. 305 - 307, http://dx.doi.org/10.1016/j.jhep.2008.06.005
,2007, 'Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection', International Journal of Drug Policy, 18, pp. 437 - 443, http://dx.doi.org/10.1016/j.drugpo.2007.01.009
,2007, 'The impact of ongoing illicit drug use on methadone adherence in illicit drug users receiving treatment for HIV in a directly observed therapy program', Drug and Alcohol Dependence, 89, pp. 306 - 309, http://dx.doi.org/10.1016/j.drugalcdep.2007.02.007
,2007, 'Methadone dosing strategies in HIV-infected injection drug users enrolled in a directly observed therapy program', Journal of Acquired Immune Deficiency Syndromes, 45, pp. 324 - 327, http://dx.doi.org/10.1097/QAI.0b013e318061b5fd
,2007, 'Reply [2]', Hepatology, 45, pp. 1331, http://dx.doi.org/10.1002/hep.21602
,2007, 'Clinical implications of mutations at reverse transcriptase codon 135 on response to NNRTI-based therapy', The open virology journal, 1, pp. 8 - 13, http://dx.doi.org/10.2174/1874357900701010008
,2007, 'Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users', Journal of Gastroenterology and Hepatology (Australia), 22, pp. 1519 - 1525, http://dx.doi.org/10.1111/j.1440-1746.2007.05032.x
,2007, 'Factors associated with spontaneous clearance of hepatitis C virus among illicit drug users', Canadian Journal of Gastroenterology, 21, pp. 447 - 451, http://dx.doi.org/10.1155/2007/796325
,2006, 'Hepatitis C virus reinfection in injection drug users', Hepatology, 44, pp. 1139 - 1145, http://dx.doi.org/10.1002/hep.21376
,2006, '578 Uptake of hepatitis C virus (HCV) treatment among injection drug users (IDUS) in Vancouver, Canada', Journal of Hepatology, 44, pp. S214 - S215, http://dx.doi.org/10.1016/s0168-8278(06)80578-7
,2006, 'Time for a Systematic Approach to the Treatment of Hepatitis C Virus Infection in Injection Drug Users', Future Virology, 1, pp. 139 - 141, http://dx.doi.org/10.2217/17460794.1.2.139
,2005, 'A systematic approach to the treatment of HIV and hepatitis C virus infection in the inner city: A Canadian perspective', Clinical Infectious Diseases, 41, http://dx.doi.org/10.1086/429500
,2022, 'Options: Exploring patients' experiences with depot buprenorphine and their motivations to discontinue', in DRUG AND ALCOHOL REVIEW, WILEY, pp. S43 - S43, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000862018700076&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2022, 'Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study', in International Journal of Drug Policy, http://dx.doi.org/10.1016/j.drugpo.2022.103706
,2021, '"WE'VE HAD A CIRCUIT BREAKER FOR AN OLD DOGMA OF MORE THAN 20 YEARS": CHANGES TO OPIOID AGONIST TREATMENT SERVICES DURING COVID-19, THE CHOICE STUDY', in DRUG AND ALCOHOL REVIEW, WILEY, pp. S59 - S59, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000715073200148&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2021, 'OPIOID OVERDOSE AND NALOXONE ACCESS AMONG PEOPLE WHO RECENTLY USED OPIOIDS OR RECEIVED OPIOID AGONIST TREATMENT IN AUSTRALIA: THE ETHOS ENGAGE STUDY', in DRUG AND ALCOHOL REVIEW, WILEY, pp. S59 - S60, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000715073200149&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'RESTORATION OF HCV-SPECIFIC T CELLS FOLLOWING DAA THERAPY IN ACUTE HCV INFECTION-SUPPORT FOR TREATMENT OF ACUTE INFECTION.', in HEPATOLOGY, WILEY, ELECTR NETWORK, pp. 613A - 614A, presented at Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), ELECTR NETWORK, 13 November 2020 - 16 November 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000574027002142&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'BARRIERS AND FACILITATORS TO ENGAGING IN HEPATITIS C MANAGEMENT AND DIRECT-ACTING ANTIVIRAL THERAPY AMONG GENERAL PRACTITIONERS AND DRUG AND ALCOHOL SPECIALISTS: THE PRACTITIONER EXPERIENCE', in DRUG AND ALCOHOL REVIEW, WILEY, pp. S9 - S9, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000494890100019&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2018, 'Drug and alcohol use patterns during and following treatment with sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use: Insights from trajectory analyses', in JOURNAL OF VIRAL HEPATITIS, WILEY, CANADA, Toronto, pp. 31 - 32, presented at 16th International Symposium on Viral Hepatitis and Liver Diseases (ISVHLD), CANADA, Toronto, 14 June 2018 - 17 June 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000435101000046&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2018, 'Evaluation of a hepatitis C virus core antigen assay in dried-blood spots: a cohort study', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, FRANCE, Paris, pp. S317 - S318, presented at International Liver Congress (ILC), FRANCE, Paris, 11 April 2018 - 15 April 2018, http://dx.doi.org/10.1016/S0168-8278(18)30854-7
,2018, 'Evaluation of the Xpert fingerstick HCV viral load assay', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, FRANCE, Paris, pp. S167 - S167, presented at International Liver Congress (ILC), FRANCE, Paris, 11 April 2018 - 15 April 2018, http://dx.doi.org/10.1016/S0168-8278(18)30546-4
,2018, 'Incidence of hepatitis C virus infection in four prisons in New South Wales, Australia: The SToP-C study', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, FRANCE, Paris, pp. S187 - S188, presented at International Liver Congress (ILC), FRANCE, Paris, 11 April 2018 - 15 April 2018, http://dx.doi.org/10.1016/S0168-8278(18)30587-7
,2017, 'EFFICACY AND SAFETY OF SOFOSBUVIR-BASED DIRECT-ACTING ANTIVIRAL THERAPIES FOR HEPATITIS C VIRUS INFECTION IN PATIENTS RECEIVING OPIOID SUBSTITUTION THERAPY', in DRUG AND ALCOHOL REVIEW, WILEY, pp. 34 - 35, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000424000500086&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2017, 'Hepatitis C Virus (HCV) Reinfection and Injecting Risk Behavior Following Elbasvir (EBR)/Grazoprevir (GZR) Treatment in Participants on Opiate Agonist Therapy (OAT): Co-STAR Part B', in HEPATOLOGY, WILEY, DC, Washington, pp. 112A - 113A, presented at 68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, DC, Washington, 20 October 2017 - 24 October 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000412089800196&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2017, 'Field evaluation of Xpert (R) HCV Viral Load point-of-care test for detection of hepatitis C virus infection by venipuncture-collected and finger-stick capillary whole-blood samples', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, pp. S709 - S709, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)31900-1
,2017, 'Incidence of hepatitis C virus infection in two maximum-security prisons in New South Wales, Australia: the SToP-C study', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, pp. S274 - S274, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)30862-0
,2017, 'Injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting, 2005-2014: the HITS-p study', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, pp. S488 - S488, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)31370-3
,2016, 'Hepatitis C virus core antigen: A simplified treatment monitoring tool among those with recent Hepatitis C virus infection, including for post-treatment relapse', in HEPATOLOGY, WILEY, MA, Boston, pp. 415A - 415A, presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), MA, Boston, 11 November 2016 - 15 November 2016, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000385493802113&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2016, 'Hepatitis C virus exposure, infection and associated risk behaviours in two maximum-security prisons in New South Wales, Australia', in HEPATOLOGY, WILEY, MA, Boston, pp. 385A - 386A, presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), MA, Boston, 11 November 2016 - 15 November 2016
,2016, 'C-EDGE CO-STAR: Risk of reinfection following successful therapy with elbasvir and grazoprevir in persons who inject drugs (PWID) receiving opioid agonist therapy (OAT)', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL, pp. 70 - 71, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000384664700128&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2016, 'C-EDGE CO-STAR: RISK OF REINFECTION FOLLOWING SUCCESSFUL THERAPY WITH ELBASVIR AND GRAZOPREVIR IN PERSONS WHO INJECT DRUGS (PWID) RECEIVING OPIOID AGONIST THERAPY (OAT)', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, pp. S771 - S771, presented at EASL International Liver Congress, SPAIN, Barcelona, 13 April 2016 - 17 April 2016, http://dx.doi.org/10.1016/S0168-8278(16)01503-8
,2016, 'COMPARING INDIVIDUAL AND POPULATION PREVENTION BENEFITS OF EARLY DIRECT-ACTING ANTIVIRAL TREATMENT FOR HCV', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, pp. S464 - S464, presented at EASL International Liver Congress, SPAIN, Barcelona, 13 April 2016 - 17 April 2016, http://dx.doi.org/10.1016/S0168-8278(16)00779-0
,2016, 'ON-TREATMENT ILLICIT DRUG USE DID NOT IMPACT TREATMENT OUTCOME DURING THERAPY WITH LEDIPASVIR-SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN IN THE PHASE 3 ION-1 STUDY', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, pp. S776 - S777, presented at EASL International Liver Congress, SPAIN, Barcelona, 13 April 2016 - 17 April 2016, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000399133800099&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2016, 'SOF/VEL FOR 12 WEEKS IS WELL TOLERATED AND RESULTS IN HIGH SVR12 RATES IN PEOPLE RECEIVING OPIOID SUBSTITUTION THERAPY', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, pp. S776 - S776, presented at EASL International Liver Congress, SPAIN, Barcelona, 13 April 2016 - 17 April 2016, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000399133800098&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2016, 'STABLE INCIDENCE OF HEPATITIS C VIRUS INFECTION AMONG PEOPLE WITH A HISTORY OF INJECTING DRUG USE IN AN AUSTRALIAN PRISON SETTING, 2005-2014: THE HITS-P STUDY', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, pp. S614 - S614, presented at EASL International Liver Congress, SPAIN, Barcelona, 13 April 2016 - 17 April 2016, http://dx.doi.org/10.1016/S0168-8278(16)01138-7
,2015, 'C-EDGE CO-STAR: Efficacy of Grazoprevir and Elbasvir in Persons who Inject Drugs (PWID) Receiving Opioid Agonist Therapy', in HEPATOLOGY, WILEY-BLACKWELL, CA, San Francisco, pp. 227A - 228A, presented at 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), CA, San Francisco, 13 November 2015 - 17 November 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000368375400041&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2015, 'Trends in end-stage liver disease among people notified with HBV or HCV in New South Wales, Australia: 2000-2014', in HEPATOLOGY, WILEY-BLACKWELL, CA, San Francisco, pp. 1121A - 1121A, presented at 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), CA, San Francisco, 13 November 2015 - 17 November 2015
,2014, 'Factors associated with hepatitis C virus RNA levels in early chronic infection: The InC3 study', in Journal of Viral Hepatitis, Blackwell Publishing Ltd, MA, Boston, pp. 708 - 717, presented at 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 07 November 2014 - 11 November 2014, http://dx.doi.org/10.1111/jvh.12384
,